Diabeloop study reveals significative sex differences in insulin requirements for Type 1 diabetes patients
Diabeloop study reveals significative sex differences in insulin requirements for...
Because Passions Should Rule One’s Life. Not Diabetes!
Diabeloop partners with patients: Since its creation, Diabeloop has been involving people living with Type 1 or Type 2 diabetes and their relatives from the very first phases of development of its innovations, alongside engineers and doctors.
The creation of intuitive interfaces for the personalized solutions developed by Diabeloop are inspired by the requests of patients and their personal experiences, so that they can spend less time on their diabetes, and more on their passions!
The International launch of a Diabeloop
Diabeloop’s first medical device is marketed in France and in several European countries.
We have signed development agreements with several international partners (Roche Diabetes Care, ViCentra, SOOIL, Terumo Corporation, BIOCORP).
In 2024, Diabeloop is accelerating its development with:
– A new €15 million funding round
– A new leadership team with the appointment of François Miceli as Chairman and CEO.
Our Latest News
New €15 Million Funding Round for Diabeloop
Appointment of François Miceli as Chairman and CEO in March...
Diabeloop At ATTD 2023
Booth, live session, e-poster, advocacy support
Reduce The Heavy Burden For People With Diabetes
Diabeloop developed a self-learning algorithm that embeds therapeutic artificial intelligence, to automate Type 1 diabetes treatment. It is intended to relieve people affected by this chronic condition from having to make constant therapeutic decisions every day and night, and to allow them to live life without interruption.
Extended partnership between Diabeloop and Terumo Corporation to develop and commercialize AID solutions in Europe
https://www.mpo-mag.com/contents/view_breaking-news/2022-02-15/terumo-and-diabeloop-partner-to-expand-diabetes-care-offerings/
Diabeloop adapts their AI algorithms to insulin pens
https://www.massdevice.com/diabeloop-announces-integration-of-insulin-automatization-software-for-use-with-insulin-pens/
Diabeloop rounds up 70 million euros to accelerate its international expansion
https://www.fiercebiotech.com/medtech/diabeloop-rounds-eu70m-take-ai-powered-insulin-delivery-tech-global
Conclusion of new global development and commercial agreements with SOOIL Development Company
https://www.massdevice.com/diabeloop-sooil-automated-insulin-diabetes/
Diabeloop completes a 70 million euros Series C to support its hyper growth
https://www.g-medtech.com/news/diabeloop-closes-e70m-series-c-financing-led-by-lbo-france/
Diabeloop and EOFlow enter into partnership agreements to co-develop a wearable AID solution with a smartphone app
https://aithority.com/technology/diabeloop-and-eoflow-partner-to-offer-a-wearable-aid-with-a-smartphone-app/?utm_source=hootsuite&utm_medium=twitter&utm_term=aithority&utm_content=53596a22-1ba5-4334-9ba7-34ce94c9e14f&utm_campaign=Organic
Connected insulin pens: Diabeloop announces a new collaboration with Novo Nordisk
https://www.contractpharma.com/contents/view_breaking-news/2023-03-21/diabeloop-novo-nordisk-partner-on-next-gen-insulin-pens/Awards
French Tech 120 2020
Start Up of the Year 2019 award
InnovEIT Award 2019
Awarding fundings in 2016-2017 and 2018-2019-2020
Trophée de l'Embarqué, Health Award
Born Global Award Start-up of the Year EY 2018
Jury Prize, Start-up of the Year SNITEM
Samsung Artificial Intelligence Award Vivatech 2018